About Caris Life Sciences
Caris Life Sciences is a company based in Irving (United States) founded in 1996. It operates as a AI-as-a-Service, Professional Services, and HealthTech. Caris Life Sciences has raised $1.23 billion across 9 funding rounds from investors including Fidelity Investments, TPG and T. Rowe Price. The company has 1,339 employees as of December 31, 2022. Caris Life Sciences has completed 1 acquisition, including Caris Life Sciences. Caris Life Sciences offers products and services including Caris Assure, MI Profile, and Caris Molecular AI. Caris Life Sciences operates in a competitive market with competitors including Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
- Headquarter Irving, United States
- Employees 1339 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Caris Life Sciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.23 B (USD)
in 9 rounds
-
Latest Funding Round
$168 M (USD), Series D
Apr 07, 2025
-
Investors
Fidelity Investments
& 19 more
-
Employee Count
1339
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Caris Life Sciences
Caris Life Sciences is a publicly listed company on the NASDAQ with ticker symbol CAI in USA, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Caris Life Sciences
Caris Life Sciences offers a comprehensive portfolio of products and services, including Caris Assure, MI Profile, and Caris Molecular AI. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Blood-based sequencing is used for deep molecular insights.
Tissue profiling is provided for comprehensive molecular blueprints.
AI solutions are applied for cancer classification insights.
Unlock access to complete
Unlock access to complete
Leadership Team
113 people
Software Development Team
75 people
Molecular Team
55 people
Senior Team
31 people
Data Analysis and Operations Team
30 people
Sales and Marketing
25 people
Account Team
22 people
Operations Team
22 people
Unlock access to complete
Funding Insights of Caris Life Sciences
Caris Life Sciences has successfully raised a total of $1.23B across 9 strategic funding rounds. The most recent funding activity was a Series D round of $168 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series D — $168.0M
-
First Round
First Round
(09 Jan 2017)
- Investors Count 20
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Series D - Caris Life Sciences | Valuation | Braidwell | |
| Jan, 2023 | Amount | Debt – Conventional - Caris Life Sciences | Valuation |
investors |
|
| May, 2021 | Amount | Series D - Caris Life Sciences | Valuation | Sixth Street |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Caris Life Sciences
Caris Life Sciences has secured backing from 20 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, TPG and T. Rowe Price. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Caris Life Sciences
Caris Life Sciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Caris Life Sciences. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Oncology-focused CRO and SMO services are provided for clinical development.
|
1987 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Caris Life Sciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Caris Life Sciences Comparisons
Competitors of Caris Life Sciences
Caris Life Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Denali Therapeutics, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Caris Life Sciences
Frequently Asked Questions about Caris Life Sciences
When was Caris Life Sciences founded?
Caris Life Sciences was founded in 1996 and raised its 1st funding round 21 years after it was founded.
Where is Caris Life Sciences located?
Caris Life Sciences is headquartered in Irving, United States. It is registered at Irving, Texas, United States.
Is Caris Life Sciences a funded company?
Caris Life Sciences is a funded company, having raised a total of $1.23B across 9 funding rounds to date. The company's 1st funding round was a Series D of $830M, raised on Jan 09, 2017.
How many employees does Caris Life Sciences have?
As of Dec 31, 2022, the latest employee count at Caris Life Sciences is 1,339.
What does Caris Life Sciences do?
Caris Life Sciences is engaged in revolutionizing cancer care through precision medicine. The company is recognized for developing innovative solutions that analyze biological networks at the molecular level. Services are provided across the care continuum, including disease detection, therapy selection, and treatment monitoring. Advanced technologies in molecular profiling and AI are utilized to inform personalized treatment decisions. The healthcare sector is primarily served, with a focus on oncology. Comprehensive databases combining genomic, transcriptomic, and proteomic data with clinical outcomes are maintained. Solutions are offered to patients, physicians, and biopharma partners to improve patient outcomes globally.
Who are the top competitors of Caris Life Sciences?
Caris Life Sciences's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
What products or services does Caris Life Sciences offer?
Caris Life Sciences offers Caris Assure, MI Profile, and Caris Molecular AI.
Is Caris Life Sciences publicly traded?
Yes, Caris Life Sciences is publicly traded on NASDAQ under the ticker symbol CAI.
How many acquisitions has Caris Life Sciences made?
Caris Life Sciences has made 1 acquisition, including Caris Life Sciences.
Who are Caris Life Sciences's investors?
Caris Life Sciences has 20 investors. Key investors include Fidelity Investments, TPG, T. Rowe Price, Orbimed, and CPP Investments.
What is Caris Life Sciences's ticker symbol?
The ticker symbol of Caris Life Sciences is CAI on NASDAQ.
What is Caris Life Sciences's valuation?
The valuation of Caris Life Sciences is $7.83B as of May 2021.